| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
37,490,000 |
| Market
Cap: |
26.24(K) |
| Last
Volume: |
125 |
Avg
Vol: |
35,949 |
| 52
Week Range: |
$0.0002 - $0.0044 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Affymax is a biopharmaceutical company in the process of restructuring operations. Co.'s U.S. Food and Drug Administration approved product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis, has been recalled. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and sales were ceased. Co. granted its collaboration partner, Takeda Pharmaceutical Company Limited, a license to OMONTYS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Naso Robert B |
EVP, Research and Development |
• – – |
2007-11-01 |
4 |
OE |
$0.80 |
$6,041 |
D/D |
7,551 |
8,170 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-10-03 |
4 |
AS |
$26.72 |
$219,691 |
D/D |
(8,163) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-10-03 |
4 |
OE |
$0.80 |
$6,530 |
D/D |
8,163 |
8,163 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-19 |
4 |
S |
$27.16 |
$81,042 |
D/D |
(2,975) |
0 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-19 |
4 |
S |
$27.00 |
$819,987 |
D/D |
(29,978) |
2,975 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-19 |
4 |
OE |
$0.80 |
$26,362 |
D/D |
32,953 |
32,953 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-18 |
4 |
S |
$27.04 |
$162,597 |
D/D |
(6,000) |
9,300 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-18 |
4 |
OE |
$0.80 |
$12,240 |
D/D |
15,300 |
15,300 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-18 |
4 |
S |
$27.14 |
$254,158 |
D/D |
(9,300) |
0 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-17 |
4 |
S |
$27.50 |
$277,174 |
D/D |
(10,000) |
0 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-09-17 |
4 |
OE |
$0.80 |
$8,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-12 |
4 |
AS |
$26.99 |
$300,068 |
D/D |
(10,727) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-12 |
4 |
OE |
$0.80 |
$8,582 |
D/D |
10,727 |
10,727 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-11 |
4 |
AS |
$25.23 |
$246,000 |
D/D |
(9,565) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-11 |
4 |
AS |
$26.47 |
$5,328,794 |
D/D |
(2,435) |
9,565 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-11 |
4 |
OE |
$0.80 |
$9,600 |
D/D |
12,000 |
12,000 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-10 |
4 |
AS |
$25.00 |
$201,463 |
D/D |
(8,000) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-10 |
4 |
OE |
$0.80 |
$6,400 |
D/D |
8,000 |
8,000 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-07 |
4 |
AS |
$25.00 |
$325,625 |
D/D |
(13,000) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-07 |
4 |
OE |
$0.80 |
$10,400 |
D/D |
13,000 |
13,000 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-06 |
4 |
AS |
$25.00 |
$300,823 |
D/D |
(12,000) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-06 |
4 |
OE |
$0.80 |
$9,579 |
D/D |
11,974 |
12,000 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-05 |
4 |
AS |
$25.00 |
$167,900 |
D/D |
(6,716) |
26 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-09-04 |
4 |
AS |
$25.00 |
$199,175 |
D/D |
(7,967) |
6,742 |
|
- |
|
| Henner Dennis |
10% Owner |
– – • |
2006-12-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,534,898 |
1,600,469 |
|
- |
|
225 Records found
|
|
Page 8 of 9 |
|
|
